三阳性乳腺癌联合治疗进展回顾
Review on the Progress of Combined Therapy for Triple-Positive Breast Cancer
DOI: 10.12677/ACM.2023.1381800, PDF,   
作者: 杨 振, 郭晨明*：新疆医科大学第一附属医院消化血管外科中心乳腺外科，新疆 乌鲁木齐
关键词: 三阳性乳腺癌；靶向治疗；联合治疗；Triple-Positive Breast Cancer (TPBC)； Targeted Therapy； Combination Therapy
摘要: 三阳性乳腺癌(TPBC)是雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2 (HER2)均为阳性的一类乳腺恶性肿瘤。TPBC与其他分子亚型乳腺癌存在明显区别，国内外许多研究认为针对TPBC患者化疗联合抗HER2靶向治疗是标准的治疗方案。随着更多靶向药物的问世，采取更加有效、安全和易被接受的治疗方案有助于病人治疗效果的提高。探讨TPBC的联合治疗，以减少复发率，提高总生存的精准治疗是未来方向。本文探讨TPBC的联合治疗选择，通过不同的治疗方案来阐述TPBC的治疗进展及展望。
Abstract: Triple-positive breast cancer (TPBC) is a malignant tumor of the breast that is positive for estrogen and progesterone receptors and human epidermal growth factor receptor2 (HER2). TPBC is dis-tinctly different from other molecular subtypes of breast cancer, and many studies in China and abroad have considered chemotherapy combined with anti-HER2-targeted therapy for TPBC pa-tients as the standard of care. As more targeted drugs become available, the adoption of more effec-tive, safe and accessible treatment options will help improve patient outcomes. It is the future di-rection to explore the combined treatment of TPBC to reduce the recurrence rate and improve the overall survival rate. This article discusses TPBC combination therapy options and illustrates the progress and outlook of TPBC treatment through different protocols.
文章引用：杨振, 郭晨明. 三阳性乳腺癌联合治疗进展回顾[J]. 临床医学进展, 2023, 13(8): 12845-12850. https://doi.org/10.12677/ACM.2023.1381800

参考文献

[1] Li, T., Mello-Thoms, C. and Brennan, P.C. (2016) Descriptive Epidemiology of Breast Cancer in China: Incidence, Mor-tality, Survival and Prevalence. Breast Cancer Research and Treatment, 159, 395-406. [Google Scholar] [CrossRef] [PubMed]
[2] Lousberg, L., Collignon, J. and Jerusalem, G. (2016) Resistance to Therapy in Estrogen Receptor Positive and Human Epidermal Growth Factor 2 Positive Breast Cancers: Progress with Latest Therapeutic Strategies. Therapeutic Advances in Medical Oncology, 8, 429-449. [Google Scholar] [CrossRef] [PubMed]
[3] Vici, P., Pizzuti, L., Natoli, C., et al. (2015) Triple Positive Breast Cancer: A Distinct Subtype? Cancer Treatment Reviews, 41, 69-76. [Google Scholar] [CrossRef] [PubMed]
[4] Popovska, S. and Ivanov, I. (2014) Lymphatic Vascularization in Primary Breast Cancer: HER2 Overexpressing Tumors Contain More Lymphatics than Steroid Receptor Positive, Tri-ple-Positive and Triple Negative Breast Carcinomas. Turkish Journal of Pathology, 30, 124-132. [Google Scholar] [CrossRef] [PubMed]
[5] 任玉琳, 张丽, 佟仲生. 不同激素状态的HER2阳性晚期乳腺癌复发转移特征及生存分析[J]. 肿瘤防治研究, 2019, 46(1): 37-44.
[6] Guan, X., Liu, B., Niu, Y., et al. (2020) Longitudinal HER2 Amplification Tracked in Circulating Tumor DNA for Therapeutic Effect Monitoring and Prognostic Evaluation in Patients with Breast Cancer. Breast, 49, 261-266. [Google Scholar] [CrossRef] [PubMed]
[7] 王冬旭, 李湘奇. 三阳性乳腺癌的病理特征及治疗分析[J]. 癌症进展, 2021, 19(6): 545-549.
[8] Cortazar, P., Zhang, L., Untch, M., et al. (2014) Pathological Complete Re-sponse and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. Lancet, 384, 164-172. [Google Scholar] [CrossRef] 
[9] 王朝斌, 王殊. 激素受体阳性、HER-2阳性乳腺癌新辅助治疗选择[J]. 中国实用外科杂志, 2021, 41(11): 1248-1252.
[10] Chen, D., Jin, L., Xu, Y., et al. (2021) ErbB Inhib-itors as Neoadjuvant Therapy for Triple-Positive Breast Cancer: A Network Meta-Analysis. American Journal of Trans-lational Research, 13, 12129-12140.
[11] Hurvitz, S.A., Martin, M., Jung, K.H., et al. (2019) Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes from the Phase III KRISTINE Study. Journal of Clinical Oncology, 37, 2206-2216. [Google Scholar] [CrossRef] 
[12] van Ramshorst, M.S., van der Voort, A., van Werkhoven, E.D, et al. (2018) Neoadjuvant Chemotherapy with or without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer (TRAIN-2): A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 19, 1630-1640. [Google Scholar] [CrossRef] 
[13] Masuda, N., Ohtani, S., Takano, T., et al. (2020) A Ran-domized, 3-Arm, Neoadjuvant, Phase 2 Study Comparing Docetaxel  + Carboplatin  +  Trastuzumab  +  Pertuzumab (TCbHP), TCbHP Followed by Trastuzumab Emtansine and Pertuzumab (T-DM1 + P), and T-DM1 + P in HER2-Positive Primary Breast Cancer. Breast Cancer Research and Treatment, 180, 135-146. [Google Scholar] [CrossRef] [PubMed]
[14] Jagiełło-Gruszfeld, A.I., Rosinska, M., Meluch, M., et al. (2022) Neoadjuvant Pertuzumab plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers, 14, Article No. 1218. [Google Scholar] [CrossRef] [PubMed]
[15] Swain, S.M., Miles, D., Kim, S.-B., et al. (2020) Per-tuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Re-sults from a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 21, 519-530. [Google Scholar] [CrossRef] 
[16] 张国泰, 符德元. 三阳性乳腺癌的治疗进展[J]. 现代肿瘤医学, 2020, 28(4): 687-690.
[17] 刘斌亮, 谢宁, 欧阳取长. 早期HR阳性/HER2阳性乳腺癌的治疗选择与思考[J]. 中国临床新医学, 2022, 15(6): 482-487.
[18] Loi, S., Dafni, U., Karlis, D., et al. (2016) Effects of Estrogen Re-ceptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. JAMA Oncology, 2, 1040-1047. [Google Scholar] [CrossRef] [PubMed]
[19] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2021) Trastuzumab for Early-Stage, Her2-Positive Breast Cancer: A Meta-Analysis of 13 864 Women in Seven Ran-domised Trials. The Lancet Oncology, 22, 1139-1150.
[20] Rasha, F., Sharma, M. and Pruitt, K. (2021) Mechanisms of Endocrine Therapy Resistance in Breast Cancer. Molecular and Cellular Endocrinology, 532, Article ID: 111322. [Google Scholar] [CrossRef] [PubMed]
[21] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J]. 中国癌症杂志, 2021, 31(10): 954-1040.
[22] Francis, P.A., Pagani, O., Fleming, G.F., et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 379, 122-137. [Google Scholar] [CrossRef] 
[23] 王汝晋, 向敏, 王绪娟. 两种新辅助治疗方案治疗HR阳性、HER-2阳性乳腺癌的疗效及安全性比较[J]. 现代肿瘤医学, 2022, 30(15): 2749-2753.
[24] Chan, A., Delaloge, S., Holmes, F.A., et al. (2016) Neratinib after Trastuzumab-Based Adjuvant Therapy in Patients with HER2-Positive Breast Cancer (EXTENET): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 17, 367-377. [Google Scholar] [CrossRef] 
[25] Kay, C., Mar-tínez-Pérez, C., Meehan, J., et al. (2021) Current Trends in the Treatment of HR+/HER2+ Breast Cancer. Future Oncol-ogy, 17, 1665-1681. [Google Scholar] [CrossRef] [PubMed]
[26] You, S.H., Chae, B.J., Eom, Y.H., et al. (2018) Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data. Journal of Breast Cancer, 21, 415-424. [Google Scholar] [CrossRef] [PubMed]
[27] Goel, S., Wang, Q., Watt, A.C., et al. (2016) Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell, 29, 255-269. [Google Scholar] [CrossRef] [PubMed]
[28] Long, F., He, Y., Fu, H., et al. (2019) Preclinical Characterization of SHR6390, a Novel CDK 4/6 Inhibitor, in Vitro and in Human Tumor Xenograft Models. Cancer Science, 110, 1420-1430. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, Y., Yuan, X., Li, J., et al. (2021) The Synergistic Effects of SHR6390 Combined with Pyrotinib on HER2+/HR+ Breast Cancer. Frontiers in Cell and Developmental Biology, 9, Article 785796. [Google Scholar] [CrossRef] [PubMed]
[30] Statler, A.B., Hobbs, B.P., Wei, W., et al. (2019) Real-World Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Anal-ysis. Scientific Reports, 9, Article No. 18126. [Google Scholar] [CrossRef] [PubMed]
[31] Hua, X., Bi, X.-W., Zhao, J.-L., et al. (2022) Trastuzumab plus Endocrine Therapy or Chemotherapy as First-Line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clinical Cancer Research, 28, 637-645. [Google Scholar] [CrossRef] 
[32] Dieci, M.V. and Guarneri, V. (2020) Should Triple-Positive Breast Cancer Be Recognized as a Distinct Subtype? Expert Review of Anticancer Therapy, 20, 1011-1014. [Google Scholar] [CrossRef] [PubMed]
[33] Giuliano, M., Trivedi, M.V. and Schiff, R. (2013) Bidirec-tional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. Breast Care, 8, 256-262. [Google Scholar] [CrossRef] [PubMed]

为你推荐